Pruritus Therapeutics Market To Reach $11.38 Billion By 2030

Pruritus Therapeutics Market Growth & Trends

The global pruritus therapeutics market size is expected to reach USD 11.38 billion by 2030, registering a CAGR of 4.0% from 2023 to 2030, according to a new report by Grand View Research, Inc. Growing worldwide prevalence of atopic dermatitis, allergic contact dermatitis, and urticaria is expected to drive market growth during the forecast period. The introduction of new products based on scientific mechanistic understanding such as the identification of new T-cell subsets, particularly Th17, and Th22 and the patent expiration of PROTOPIC (tacrolimus) is expected to open up new avenues for manufacturers to capitalize on over the forecast period. 

Corticosteroids were the leading product segment in 2013 owing to high efficacy exhibited by this class of drugs in treating pruritic conditions by reducing inflammation and itching. Topical applications of corticosteroids have been found to be extremely effective in the treatment and maintenance therapies pertaining to pruritus.

 Request a free sample copy or view report summary: Pruritus Therapeutics Market Report

Pruritus Therapeutics Market Report Highlights

• Calcineurin inhibitor is identified as the most lucrative segment of the market on account of the high usage rate of these drugs in combination therapy for the treatment of pruritus in patients suffering from chronic pruritus and growing market penetration rates. Moreover, the introduction of new products such as Pimecrolimus cream and Tacrolimus ointment is expected to further drive this market.

• Anti-histamines owing to its growing use as a first-line treatment and presence of drugs in pipeline with expected commercialization is also expected to grow at a healthy rate during the forecast period.

• North America dominated the market and accounted for the largest revenue share of 39.9% in 2022. majorly on account of the presence of a high prevalence of diseases associated with pruritus, the introduction of new products targeting the unmet medical needs, and growing patient awareness levels.

• The Asia Pacific pruritus therapeutics market is expected to grow at a CAGR of over 5.0% during the forecast period. The presence of high unmet healthcare needs and increasing prevalence of allergic contact dermatitis and urticaria in this region are some factors attributing to its rapid growth rate.

• Manufacturers adhere to rigorous R&D in an attempt to develop cost-effective products and avoid barriers such as product recalls. In addition, this strategy is implemented keeping the unmet needs into consideration. For Instance, Creabilis has a molecule in the pipeline - CT327, which caters to the unmet needs associated with pruritus in patients suffering from psoriasis.

Pruritus Therapeutics Market Segmentation

Grand View Research has segmented the global pruritus therapeutics market on the basis of disease type, product, and region:

Pruritus Therapeutics Disease Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Atopic Dermatitis

• Allergic Contact Dermatitis

• Urticaria

• Others

Pruritus Therapeutics Product Outlook (Revenue, USD Billion, 2018 - 2030)

• Corticosteroids

• Antihistamines

• Local Anesthetics

• Counterirritants

• Immunosuppressant

• Calcineurin Inhibitors

• Others

Pruritus Therapeutics Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

List of Key Players in the Pruritus Therapeutics Market

• Abbvie, Inc.

• Actavis Plc

• Amgen, Inc.

• Astellas Pharma

• Bristol-Myers Squibb

• Cara Therapeutics

• GlaxoSmithKline, Plc.

• Myaln NV

• Novartis AG

• Pfizer Inc.

• Sanofi

• Teva Pharmaceuticals